OncoGenex Technologies and Isis Pharmaceuticals Expand Partnership

OncoGenex Technologies and Isis Pharmaceuticals announced they have broadened their antisense drug development partnership to allow for the development of two additional second-generation antisense anticancer drug candidates. OncoGenex and Isis initiated a partnership in December 2001 to co-develop OGX-011, a drug currently in Phase I/II development for the treatment of prostate, breast and lung cancers. In 2003, OncoGenex and Isis added a second drug to their collaboration, OGX-225, which is in the research phase of development.

Yahoo News (http://biz.yahoo.com/prnews/050316/law037_3.html)